Cost-effectiveness of gemifloxacin: Results from the GLOBE study

American Journal of Health-System Pharmacy

Volumn 59, Issue 14, 2002, Pages 1357-1365

  Halpern, Michael T ^a   Palmer, Cynthia S ^a   Zodet, Marc ^a   Kirsch, Jeff ^a  

^a EXPONENT INC   (United States)

Author keywords

Bronchitis; Clarithromycin; Costs; Drug comparisons; Drugs, clinical effectiveness; Economics; Gemifloxacin; Macrolides; Outcomes

Indexed keywords

CLARITHROMYCIN; GEMIFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESOURCE ALLOCATION;

EID: 0037100559     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.14.1357     Document Type: Article

References (30)

1. Therapeutic challenges of acute bacterial exacerbation of chronic bronchitis
2. The Alexander Project 1998: Comparative in vitro activity of 20 antimicrobial agents against 2975 community-acquired respiratory tract isolates
3. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
4. Causes, epidemiology and treatment of bronchial infections
5. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis
6. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy
7. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
8. Global resistance patterns of quinolones, macrolides, and β-lactams from a multi-center, multi-country study of >9,000 isolates: The gemifloxacin surveillance study
9. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis
10. Treatment cost of acute exacerbations of chronic bronchitis
11. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis
12. Acute exacerbations of chronic bronchitis
13. Bronchitis
14. Airway infection
15. How do we achieve cost-effective options in lower respiratory tract infection therapy?
16. Con: Antibiotic use in exacerbations of chronic bronchitis
17. A 1-year community-based health economic study of ciprofloxacin vs. usual antibiotic treatment in acute exacerbations of chronic bronchitis: The Canadian Ciprofloxacin Health Economic Study Group
18. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
19. Gemifloxacin Long-term Outcomes in Bronchitis Exacerbations (GLOBE) study: An assessment of health outcome benefits in AECB patients following 5 days gemifloxacin therapy
20. A comparison of gemfloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes
21. Estimating costs in cost-effectiveness analysis
22. Reflecting uncertainty in cost-effectiveness analysis
23. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care
24. Confidence intervals for cost-effectiveness ratios: A comparison of four methods
25. Definition, interpretation and calculation of cost-effectiveness acceptability curves
26. Theoretical foundations of cost-effectiveness analysis